ArticleAlzheimer's research & therapy2023
A metagenomic study of gut viral markers in amyloid-positive Alzheimer's disease patients.
Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Gut microbiome in type 2 diabetes: insights from metagenomics, multi-omics, and diet-microbe interactions.Gut microbes · 2026Review
- Mind the Gut: Cognitive Decline, Microbiota, and Nutrition-Related Modulators in Older Adults with Chronic Kidney Disease.Nutrients · 2026Review
- Silent Intruders: The Gut Virome in Brain Aging and Cognitive Decline.Pathogens (Basel, Switzerland) · 2026Review
- Gut microbiota and cognitive decline: a scoping review of microbial mechanisms and adaptive responses in dementia.Frontiers in aging neuroscience · 2026Review
- Microbiota-derived metabolites and cognitive dysfunction in dialysis patients: mechanisms and targeted therapeutic strategies.Frontiers in microbiology · 2026Review
- Exploring the role of infectious pathogens in Alzheimer's disease neuroinflammation.Frontiers in cellular and infection microbiology · 2026Review
- Article
- Post sleeve gastrectomy-enriched gut commensal Clostridia promotes secondary bile acid increase and weight loss.Gut microbes · 2025Article
- Viewing Psychiatric Disorders Through Viruses: Simple Architecture, Burgeoning Implications.Neuroscience bulletin · 2025Review
- Phage-Microbiota Crosstalk: Implications for Central Nervous System Disorders.International journal of molecular sciences · 2025Review
- The gut virome and human health: From diversity to personalized medicine.Engineering microbiology · 2025Review
- Gut microbial and functional signatures in breast cancer: an integrated metagenomic and machine learning approach to non-invasive detection.Frontiers in microbiology · 2025Article
- The gut and circulating virome: emerging players in aging and longevity.Frontiers in aging · 2025Review
- Bacteriophages: a double-edged sword in the gastrointestinal tract.Frontiers in microbiomes · 2024Review
- Cingulate white matter mediates the effects of fecal Ruminococcus on neuropsychiatric symptoms in patients with amyloid-positive amnestic mild cognitive impairment.BMC geriatrics · 2023Article
- Abnormalities in gut virome signatures linked with cognitive impairment in older adults.Gut microbesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMounting evidence suggests the involvement of viruses in the development and treatment of Alzheimer's disease (AD). However, there remains a significant research gap in metagenomic studies investigating the gut virome of AD patients, leaving gut viral dysbiosis in AD unexplored. This study aimed to fill this gap by conducting a metagenomics analysis of the gut virome in both amyloid-positive AD patients (Aβ + ADs) and healthy controls (HCs), with the objective of identifying viral signatures linked with AD.
methodWhole-genome sequence (WGS) data from 65 human participants, including 30 Aβ + ADs and 35 HCs, was obtained from the database NCBI SRA (Bio Project: PRJEB47976). The Metaphlan3 pipeline and linear discriminant analysis effect size (LEfSe) analysis were utilized for the bioinformatics process and the detection of viral signatures, respectively. In addition, the Benjamini-Hochberg method was applied with a significance cutoff of 0.05 to evaluate the false discovery rate for all biomarkers identified by LEfSe. The CombiROC model was employed to determine the discriminatory power of the viral signatures identified by LEfSe.
resultsCompared to HCs, the gut virome profiles of Aβ + ADs showed lower alpha diversity, indicating a lower bacteriophage richness. The Siphoviridae family was decreased in Aβ + ADs. Significant decreases of Lactococcus phages were found in Aβ + ADs, including bIL285, Lactococcus phage bIL286, Lactococcus phage bIL309, and Lactococcus phage BK5 T, Lactococcus phage BM13, Lactococcus phage P335 sensu lato, Lactococcus phage phiLC3, Lactococcus phage r1t, Lactococcus phage Tuc2009, Lactococcus phage ul36, and Lactococcus virus bIL67. The predictive combined model of these viral signatures obtained an area under the curve of 0.958 when discriminating Aβ + ADs from HCs.
conclusionThis is the first study to identify distinct viral signatures in the intestine that can be used to effectively distinguish individuals with AD from HCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.